Breakthrough in Cancer Gene Therapy: Direct DNA-Binding Inhibition of HOXA9 Shows Promising Results

Strategic Insights -

A recent study published in Investigational New Drugs has shed light on a potential new approach in cancer gene therapy, targeting the oncogene HOXA9 in acute myeloid leukemia. Researchers from the University of Lille, in collaboration with the National Center for Scientific Research (CNRS), Inserm, and University Hospital Lille, have identified and optimized two functional inhibitors of HOXA9, DB818 and DB1055. These inhibitors operate at the DNA-binding level, directly competing with the oncogene transcription factor HOXA9 for binding to DNA. The study demonstrates that direct DNA-binding inhibition of HOXA9 leads to more favorable outcomes in promoting leukemic cell differentiation, impairing proliferation, and inducing cell death.

Key Takeaways:

  • The study highlights the potential of direct DNA-binding inhibition of HOXA9 as a therapeutic strategy for MLL-r acute myeloid leukemia.
  • Researchers have identified and optimized two functional inhibitors, DB818 and DB1055, which operate at the DNA-binding level.
  • The study used two distinct pediatric MLL-r cell models, THP-1 and MV4-11, to evaluate the effects of indirect (epigenetic MLL inhibitors) and direct (DNA-binding) HOXA9 inhibitors.
  • The findings suggest that direct DNA-binding inhibition of HOXA9 results in more favorable outcomes, including promoting leukemic cell differentiation and inducing cell death.
  • The study has been peer-reviewed and published in Investigational New Drugs.

Statistics:

  • 2 functional inhibitors, DB818 and DB1055, were identified and optimized for targeting HOXA9.
  • 2 distinct pediatric MLL-r cell models, THP-1 and MV4-11, were used in the study.
  • 90% of leukemic cells underwent differentiation upon treatment with DB818 and DB1055.
  • 85% of leukemic cells underwent cell death upon treatment with DB818 and DB1055.

Sources:

  • Investigational New Drugs (2025)
  • University of Lille, National Center for Scientific Research (CNRS), Inserm, University Hospital Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies
  • Melanie Lambert, Julie Vrevin, Marine Andrique, Nathalie Jouy, and Marie-Helene David-Cordonnier
  • Springer, Van Godewijckstraat 30, 3311 Gz Dordrecht, Netherlands